Rinucumab

Rinucumab
Monoclonal antibody
Type	?
Source	Human
Target	platelet-derived growth factor receptor beta
Clinical data
Other names	REGN2176
ATC code	none;
Identifiers
CAS Number	1569263-06-4;
ChemSpider	none;
UNII	10E3O6YI4W;
Chemical and physical data
Formula	C6472H9974N1710O2022S38
Molar mass	145309.21 g·mol−1

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Rinucumab (REGN2176) is a monoclonal antibody designed for the treatment of neovascular age-related macular degeneration.^[1]^[2]

This drug was developed by Regeneron Pharmaceuticals, Inc.

References

^ "Rinucumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
^ Hussain RM, Ciulla TA (September 2017). "Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration". Expert Opinion on Emerging Drugs. 22 (3): 235–246. doi:10.1080/14728214.2017.1362390. PMID 28756707. S2CID 3505145.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

[1] "Rinucumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.

[Hussain_2017-2] Hussain RM, Ciulla TA (September 2017). "Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration". Expert Opinion on Emerging Drugs. 22 (3): 235–246. doi:10.1080/14728214.2017.1362390. PMID 28756707. S2CID 3505145.

[1]

[2]